Seasonal Influenza Vaccine Effectiveness, 2016-2017
Age | Number | % Total |
---|---|---|
6 months-8 years | 1,519 | 21 |
9-17 years | 1011 | 15 |
18-49 years | 2,165 | 31 |
50-64 years | 1,362 | 19 |
65+ years | 1026 | 14 |
Gender | Number | % Total |
---|---|---|
Male | 2,993 | 42 |
Female | 4,090 | 58 |
On This Page
- Patients by Age
- Patients by Gender
- Patients by Race
- Influenza Virus Type And Subtype Among Influenza-Positive Patients
- Vaccine Effectiveness for all Vaccine Types Against influenza A or B viruses
- Vaccine Effectiveness for all Vaccine Types Against Influenza A (H3N2) viruses
- Vaccine Effectiveness for all Vaccine Types Against Influenza B/Yamagata lineage viruses
- Vaccine Effectiveness for all Vaccine Types Against Influenza B/Victoria lineage viruse
Race | Number | % Total |
---|---|---|
White, non-Hispanic | 5,337 | 76 |
Black, non-Hispanic | 550 | 8 |
Hispanic | 607 | 9 |
Other, non-Hispanic | 571 | 8 |
2Coinfections are present in this dataset: 5 co-infections with more than one influenza virus type/subtype
Top of Page Top of Page- Page last reviewed: September 4, 2018
- Page last updated: September 4, 2018
- Content source:
- Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD)
- Page maintained by: Office of the Associate Director for Communication, Digital Media Branch, Division of Public Affairs